Fluoroquinolones (FQs) are a group of bactericidal antibiotics acting on DNA gyrase and have a high activity against *Mycobacterium tuberculosis* (*Mtb*). These are classified as group A drugs by the World Health Organization (WHO) and form the backbone of multidrug/extensively drug-resistant TB (M/XDR-TB) treatment due to their good oral bioavailability, affordable cost and excellent safety profile[@ref1]. Due to widespread prescription of FQs for trivial infections and their easy availability over the counter (OCT) in India, resistance to these drugs has remarkably increased, and this poses a major challenge to the clinicians, as it takes away a very potent weapon from the armamentarium against M/XDR-TB treatment[@ref2]. The emergence of resistance to FQs also accelerates the progression of disease among multidrug-resistant (MDR) patients and is a risk factor for the development of XDR-TB[@ref3]. Even treatment-naïve and drug-sensitive TB patients are at risk of FQs resistance[@ref4] making it imperative to assess FQs resistance at the outset before initiating therapy, especially in TB high-endemic areas[@ref5].

According to the WHO TB Report (2017), the prevalence of any FQs resistance \[drug susceptibility testing (DST) done for ofloxacin (OFX), levofloxacin (LFX) and moxifloxacin (MFX)\] among MDR-TB patients was 21 per cent globally[@ref5]. Testing for FQs resistance before starting therapy is rarely done in sputum specimens in treatment-naïve as well as in treatment-experienced TB patients, and this leads to lack of quality data regarding the same. The present observational study was carried out in a tertiary care centre in north India to find FQs resistance among smear-positive pulmonary TB patients.

Material & Methods {#sec1-2}
==================

A total of 1619 consecutive smear-positive pulmonary TB (PTB) patients were enrolled for diagnosis of MDR-TB at the Intermediate Reference Laboratory (IRL) of the All India Institute of Medical Sciences, New Delhi, between August 2013 and January 2016 after obtaining written informed consent and detailed drug treatment history. Institutional Ethics Committee approved the study protocol. Two slides for acid-fast bacilli were made directly from each sample collected from spot and morning sputum specimens and stained by Ziehl-Neelsen method as per the Revised National Tuberculosis Control Programme (RNTCP) guidelines[@ref6]. All samples were handled in the biosafety level III (BSL-III) laboratory in class-II biosafety cabinet following standard decontamination protocol, using NALC-NaOH (N-acetyl-L-cysteine-sodium hydroxide) method[@ref7]. After centrifugation, the supernatant was discarded, and the pellet was dissolved in 1-1.5 ml of phosphate buffer saline. Only 0.5 ml of this concentrated sample was inoculated on BACTEC Mycobacterial Growth Indicator Tube (MGIT-960) liquid culture medium (Becton Dickinson, Sparks, MD, USA) containing 7 ml of 7H9 supplemented with 0.8 ml of oleic acid-albumin-dextrose-catalase along with polymyxin B-amphotericin B-nalidixic acid-trimethoprim-azlocillin. The positive tubes by MGIT-960 underwent sterility check on brain heart infusion agar to rule out contamination. The immunochromatographic assay (ICA) was performed to distinguish *Mtb* complex (MTBC)from non-MTBC. The DST for first-line \[streptomycin (S) 1.0 μg/ml, isoniazid (H) 0.1 μg/ml, rifampicin (R) 1.0 μg/ml and ethambutol (E) 5.0 μg/ml\], and the second-line \[kanamycin (KM) 2.5 μg/ml, OFX 2.0 μg/ml, LFX 2.0 μg/ml and MFX 2.0 μg/ml\] anti-TB drugs was performed on pure *Mtb* isolates using BACTEC MGIT-960 system as per the standard operating procedure according to the manufacturer\'s instruction[@ref7].

Results & Discussion {#sec1-3}
====================

Of the 1619 smear-positive PTB patients, 1104 (68%) were male and 515 (32%) were female patients with mean age of 34±14.5 yr. A total of 1520 (93.9%) samples from the patients were culture positive by MGIT-960; among these 1499 (98.6%) were identified as MTBC and 21 (1.4%) were negative for MTBC by ICA. All the MDR-TB isolates among treatment naïve and treatment experienced patients were subjected to second-line DST ([Figure](#F1){ref-type="fig"}). In the remaining 1499 *Mtb* culture specimens, 385 patients were newly diagnosed and 1114 patients were TB treatment-experienced patients. A total of 249 MDR-TB patients were detected in this study, of whom 19 (4.9%; 19/385) were new cases and 230 (20.6%; 230/1114) were previously treated TB patients. The second-line drug (SLDs) DST patterns were available for 249 MDR *Mtb* isolates; 67.5 per cent (168/249) isolates were found to be susceptible to all the SLDs. Resistance to OFX was found in 27.3 per cent (68/249) isolates, and resistance to KM was observed in 0.8 per cent (2/249) MDR *Mtb* isolates. The FQ resistance (OFX) among drug-sensitive *Mtb* isolates was 3.2 per cent (35/1099). The prevalence of XDR-TB among MDR *Mtb* isolates was 3.21 per cent (8/249) ([Table](#T1){ref-type="table"}). The cross-resistance between LFX and OFX was observed in two isolates while between LFX, OFX and MFX, was seen in one isolate. All cases of KM resistance and XDR-TB occurred in treatment-experienced TB patients only.
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Drug susceptibility patterns in 249 multidrug-resistant *M. tuberculosis* isolates to second-line anti-tuberculosis drugs

  Drug resistance pattern   Number of isolates (%)
  ------------------------- ------------------------
  One-drug resistance       
  OFX                       68 (27.3)
  KM                        2 (0.80)
  LFX                       --
  MFX                       --
  Two-drug resistance       
  KM + OFX                  6 (2.40)
  LFX + OFX                 2 (0.80)
  Three-drug resistance     
  LFX + OFX + MFX           1 (0.40)
  LFX + OFX + KM            1 (0.40)
  Four-drug resistance      
  KM + OFX + LFX + MFX      1 (0.40)
  All sensitive isolates    
  KM + OFX + LFX + MFX      168 (67.4)

Data in parentheses are percentages. MDR-TB, multidrug-resistant tuberculosis; KM, kanamycin (2.5 µg/ml); OFX, ofloxacin (2 µg/ml); LFX, levofloxacin (2 µg/ml); MFX, moxifloxacin (2 µg/ml)

Indiscriminate use of FQs for a variety of infections such as respiratory tract, genitourinary tract, gastrointestinal tract, skin and ocular infections and initiating anti-TB therapy with FQs in drug sensitive TB patients in a high-endemic country like India has contributed to the rapid emergence of resistance to this class of anti-TB drugs[@ref8][@ref9][@ref10][@ref11]. Studies also report that as small as 13 days of exposure to FQs can lead to the development of FQs resistance among treatment naïve and treatment-experienced TB patients[@ref8]. Jain *et al*[@ref4] from Lucknow, north India, and Selvakumar *et al*[@ref9] from Tamil Nadu reported FQs resistance among MDR-TB patients as 26 and 29 per cent, respectively, which was similar to the present study. A drug resistance surveillance (DRS) study conducted by Ramachandran *et al*[@ref12] in Gujarat, 2009, reported FQs monoresistance to be 24 per cent with no significant difference between treatment-naïve and treatment-experienced TB patients. A recent study from a national reference laboratory in India showed 32 per cent of FQ resistance among MDR-TB isolates before treatment with second-line anti-TB drugs; the study had a higher rate of FQs resistance as their facility received mostly defaulter cases[@ref13]. India\'s first National DRS (NDRS) for MDR-TB was completed by the National Tuberculosis Institute, Bengaluru, Karnataka and the report of NDRS will have important public health implications in the prevention and control of TB disease as it will be truly representative sample of various States of India[@ref14].

In the present study 3.2 per cent FQs monoresistance was observed among drug sensitive *Mtb* isolates, which further highlighted the need to use these drugs judiciously and regulate their availability stringently. The presence of FQs resistance among drug sensitive *Mtb* isolates in the present study may be due to indiscriminate use of some commonly available quinolones for the treatment of various infections[@ref15][@ref16][@ref17].

The strength of the present study was that isolation, identification and DST of all positive *Mtb* isolates were carried out in the RNTCP-certified IRL laboratory having quality assured BSL-III laboratory facility and the limitations included the use of liquid culture with high contamination rates. Acquisition of FQ resistance among *Mtb* isolates is a matter of concern and is a contribution to the development of XDR-TB[@ref14].

In conclusion, increasing FQ resistance among treatment-naive and treatment-experienced TB patients is a matter of concern. It is suggested to test sputum and other specimens of pulmonary TB patients for FQ and other second-line anti-TB drugs resistance. Since we have limited options for the treatment of XDR-TB, all efforts should be directed to create awareness among practicing doctors to use these drugs with discretion.
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